We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

We read with considerable interest the 2023 study conducted by Yu et al., entitled ‘Minocycline versus tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial’ [1]. This study offers valuable insights, expanding the array of treatment options for Helicobacter pylori. Nonetheless, there are specific concerns that warrant attention.

A particularly striking finding in this research is the elevated incidence of dizziness, reported in 81 out of 184 participants in the minocycline group. This substantial rate of occurrence prompts critical questions regarding the feasibility of this treatment approach. Moreover, the observed 89.6% resistance rate to Metronidazole underscores the necessity for more in-depth analysis.

In response to these observations, we advocate for a thorough disclosure and discussion of the data concerning dizziness. It is essential that this includes comprehensive details about the intensity, duration, and overall impact on the patients' well-being. We are of the opinion that such information is vital for readers to make informed decisions regarding treatment options and would be instrumental in assessing therapeutic choices.